{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:06:59Z","timestamp":1793117219097,"version":"4.5.0"},"reference-count":204,"publisher":"American Society for Clinical Investigation","issue":"11","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"DOI":"10.1172\/jci170236","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T18:02:10Z","timestamp":1685556130000},"source":"Crossref","is-referenced-by-count":105,"title":["Preparing for the next viral threat with broad-spectrum antivirals"],"prefix":"10.1172","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-3962","authenticated-orcid":false,"given":"Marwah","family":"Karim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1890-4916","authenticated-orcid":false,"given":"Chieh-Wen","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirit","family":"Einav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1089\/bsp.2004.2.186"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ento.49.061802.123422"},{"key":"B3","unstructured":"Tufts Center for the Study of Drug Development, Tufts University. Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion. https:\/\/f.hubspotusercontent10.net\/hubfs\/9468915\/TuftsCSDD_June2021\/pdf\/pr-coststudy.pdf Updated November 18, 2014. Accessed April 20, 2023"},{"issue":"9","key":"B4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009929","article-title":"In vitro selection of remdesivir resistance suggests evolutionary predictability of SARS-CoV-2","volume":"17","author":"Szemiel","year":"2021","journal-title":"PLoS Pathog"},{"issue":"678","key":"B5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq7360","article-title":"SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376","volume":"15","author":"Heilmann","year":"2022","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature17180"},{"key":"B7","article-title":"How antiviral pill molnupiravir shot ahead in the COVID drug hunt","author":"Willyard","journal-title":"Nature"},{"issue":"5","key":"B8","doi-asserted-by":"crossref","first-page":"e03331","DOI":"10.1128\/spectrum.03331-22","article-title":"Combinations of host- and virus-targeting antiviral drugs confer synergistic suppression of SARS-CoV-2","volume":"10","author":"Wagoner","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1251"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.483"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1008535"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02701-15"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt111"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198601023140104"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.01.055"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1635009"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/v11040326"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9242"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104541"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2423-5"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00071"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"issue":"1","key":"B27","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/d41573-021-00202-8","article-title":"A tale of two antiviral targets \u2014 and the COVID-19 drugs that bind them","volume":"21","author":"Cully","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00570-1"},{"issue":"5","key":"B29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2208822","article-title":"VV116 versus nirmatrelvir-ritonavir for oral treatment of Covid-19","volume":"388","author":"Cao","year":"2022","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01537-21"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02346-12"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00649-13"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.02.014"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.93.027"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.10.069"},{"issue":"10","key":"B37","first-page":"1192","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"B38","article-title":"Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00517-4"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-021-00452-9"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.12.026"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw571"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001967"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00541-3"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-021-00651-0"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104597"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax5866"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105453"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03312-w"},{"issue":"628","key":"B51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2021","journal-title":"Sci Transl Med"},{"issue":"6","key":"B52","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00644-2"},{"issue":"1","key":"B54","first-page":"e01925","article-title":"Cidofovir diphosphate inhibits adenovirus 5 DNA polymerase via both nonobligate chain termination and direct inhibition, and polymerase mutations confer cidofovir resistance on intact virus","volume":"63","author":"Chamberlain","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/v2122740"},{"issue":"1","key":"B56","article-title":"Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model","volume":"6","author":"Hutson","year":"2021","journal-title":"mSphere"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00228-6"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.12.621"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749721"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.038"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.10.010"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ395"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162199"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2008.07.030"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104786"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.2003.012658"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32013-4"},{"issue":"3","key":"B69","doi-asserted-by":"crossref","first-page":"e01114","DOI":"10.1128\/mBio.01114-20","article-title":"Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets","volume":"11","author":"Park","year":"2020","journal-title":"mBio"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw551"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130062"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13642"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1177\/24725552211000652"},{"issue":"3","key":"B74","first-page":"255","article-title":"Evaluation of sinefungin for the treatment of Trypanosoma (Nannomonas) congolense infections in goats","volume":"37","author":"Zweygarth","year":"1986","journal-title":"Trop Med Parasitol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.129197"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.179184"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17495-9"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-022-00828-1"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.013"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617020114"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-007-0974-5"},{"issue":"3","key":"B82","first-page":"56","article-title":"Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)","volume":"91","author":"Pshenichnaya","year":"2019","journal-title":"Ter Arkh"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05698-w"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.11.05017"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00890"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav4580"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2460"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2018.05.011"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1021\/nl3029637"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/ph14040304"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-018-0194-2"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.1c00096"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128686"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01908-x"},{"issue":"1","key":"B95","article-title":"An intranasal ASO therapeutic targeting SARS-CoV-2","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat Commun"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89857"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104966"},{"key":"B98","doi-asserted-by":"crossref","unstructured":"Saul S, et al. Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen [preprint]. https:\/\/doi.org\/10.1101\/2021.05.15.444128 Posted on bioRxiv June 15, 2021","DOI":"10.1101\/2021.05.15.444128"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.03.001"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.03.020"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4149\/av_2014_04_374"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/ph12040142"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.0c00343"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2017.11.022"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.69.4.2451-2461.1995"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52237"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26982"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.07.019"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202108-1830LE"},{"issue":"5","key":"B110","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13371","article-title":"COVID-19 in kidney transplant recipients: a multicenter experience in Istanbul","volume":"22","author":"Demir","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.12.008"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/v8030071"},{"issue":"2","key":"B113","first-page":"139","article-title":"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells\/mm3","volume":"7","author":"Fischl","year":"1994","journal-title":"J Acquir Immune Defic Syndr (1988)"},{"issue":"8","key":"B114","first-page":"860","article-title":"Celgosivir, an \u03b1-glucosidase I inhibitor for the potential treatment of hepatitis C virus infection","volume":"10","author":"Durantel","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70730-3"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.046"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2011.11.007"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.12.095"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/v12121423"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.9b00376"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.12.010"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/nature18631"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.054"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201802044RR"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103712"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02983-21"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.722"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008900"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2341"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00750-12"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.11.006"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.01.154"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2022.09.005"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0923"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006288"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101956"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105367"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00613"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00136"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02705-14"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2013.05.010"},{"issue":"34","key":"B142","doi-asserted-by":"crossref","first-page":"20803","DOI":"10.1073\/pnas.2007837117","article-title":"Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2","volume":"117","author":"Kang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.7401155"},{"key":"B144","article-title":"Phase 1 clinical safety, pharmacokinetics (PK), and activity of apilimod dimesylate (LAM-002A), a first-in-class inhibitor of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), in patients with relapsed or refractory B-cell malignancies","volume":"130","author":"Harb","year":"2017","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2019.114771"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21159"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/art.34339"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03766-2"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.7b00268"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505577102"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.35.203"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/BF01718208"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00970-21"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02518-7"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103856"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i27.8293"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21232"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040061"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.820131"},{"issue":"3","key":"B161","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00716-15","article-title":"Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers","volume":"6","author":"Fedson","year":"2015","journal-title":"mBio"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-16357-2"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137536"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.10.030"},{"issue":"4","key":"B165","first-page":"468","article-title":"Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Whitehorn","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20248"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006257"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-020-00692-3"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87707-9"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101752"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0375"},{"key":"B172","article-title":"Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: the TOGETHER randomized platform clinical trial","volume":"6","author":"Reis","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.16053.2"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103270"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.5b00030"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/srep41226"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00853-4"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M704418200"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01943-21"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27951"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101450"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac136"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.07.014"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-11-10"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.029470"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.11.010"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04246-w"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.08.005"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70717-0"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.11.037"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000492"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100981"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01814-10"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00632-13"},{"key":"B195","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/DDDT.S30946","article-title":"Profile of alisporivir and its potential in the treatment of hepatitis C","volume":"7","author":"Gallay","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"B196","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/jcph.2161","article-title":"Potential drug interaction between favipiravir and warfarin in patients with COVID-19: a real-world observational study","volume":"63","author":"Wattana","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003030"},{"key":"B198","article-title":"FDA no longer needs to require animal tests before human drug trials","volume":"379","author":"Wadman","year":"2023","journal-title":"Science News"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.68"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1177\/1740774515621721"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.01.033"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01034-w"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13957"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa3778"}],"container-title":["Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jci.org\/articles\/view\/170236\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T17:48:30Z","timestamp":1691084910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jci.org\/articles\/view\/170236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":204,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2023,6,1]]}},"alternative-id":["10.1172\/JCI170236"],"URL":"https:\/\/doi.org\/10.1172\/jci170236","relation":{},"ISSN":["1558-8238"],"issn-type":[{"value":"1558-8238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"article-number":"e170236"}}